Abdurrahman ÇETİN, Mehmet Tahir GÖKDEMİR, Cemal NAS, Gul Sahika GOKDEMİR

Relation of neural tube defects with folic acid use during pregnancy

Aim: The objective of this study was to investigate the rate of neural tube defects (NTD) and the clinical features of newborns of mothers who did not use folic acid (FA) in their pregnancies.Material and methods: The data of a total of 82 newborns, who were diagnosed with meningomyelocele were operated and examined, retrospectively. The newborns were divided into two groups depending on whether their mothers used FA during pregnancy or not.Results: The mothers of 37 (45.1%) newborns used FA during the antenatal period, whereas those of 45 (54.9%) newborns did not.The mean birth weight of the newborns whose mothers did not use FA were lower. Furthermore 9 (25%) newborns whose mothers did not use FA were delivered via cesarean section.The incidence of meningomyelocele was 80% for 45 newborns with NTDs whose mothers did not use FA.Conclusion: Our results revealed that the mean birth weight was lower while the incidence of meningomyelocele was significantly higher in newborn infants whose mothers did not use FA.

PDF

___

1. Greene S, Lee PS, Deibert CP, et al. The impact of mode of delivery on infant neurologic outcomes in myelomeningocele.Am J Obstet Gynecol 2016;215:495.e1-495.
2. KIinsman SL, Johnston MV. Congenital anomalies of the central nervous system. In: Kliegman RM, Stanton BF, Geme JW, Schor NF, eds. Nelson Textbook of Pediatrics, 20th ed. Philadelphia: Saunders; 2016. p. 2802-19.
3. Senousy SM1, Farag MK1, Gouda AS, et al. Association between biomarkers of vitamin B12 status and the risk of neural tube defects. J. Obstet. Gynaecol Res 2018;44:1902.
4. Food and Drug Administration. Food standards of identity for enriched grain products to require addition of FAfolic acid. Final Rule 21 CFR 1996;131:3702-37.
5. Au KS, Ashley-Koch A, Northrup H. Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev Disabil Res Rev 2010;16:6-15.
6. Dolin CD, Deierlein AL, Evans MI. FA Supplementation to Prevent Recurrent Neural Tube Defects: 4 Milligrams Is Too Much. Fetal Diagn Ther 2018;44:161-5
7. Caudill MA, Le T, Moonie SA, Esfahani ST, et al. Folate status in women of childbearing age residing in Southern California after FA fortification. J Am Coll Nutr 2001;20:129-34.
8. Molloy AM, Kirke PN, Troendle JF, et al. Maternal vitamin B- 12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no FA fortification. Pediatrics 2009;123:917-23.
9. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Folic acid supplementation for the prevention of neural tube defects: us preventive services task force recommendation statement. JAMA 2017;317:183-9.
10. Nishigori H, Obara T, Nishigori T, et al. Preconception folic acid supplementation use and the occurrence of neural tube defects in Japan: A nationwide birth cohort study of the Japan Environment and Children’s Study. Congenit Anom (Kyoto) 2018;13.
11. Levine SZ, Kodesh A, Viktorin A, et al. Association of maternal use of folic acid and multivitamin supplements in the periods before and during pregnancy with the risk of autism spectrum disorder in offspring. JAMA Psychiatry 2018;75:176-84.
12. Sandford MK, Kissling GE, Joubert PE. Neural tube defect etiology: New evidence concerning maternal hyperthermia,health and diet. Dev Med Child Neurol 1992;34:661-75.
13. Ergül Tunçbilek. Türkiye’deki yüksek nöral tüp defekti sıklığı ve önlemek için yapılabilecekler. Çocuk Sağlığı ve Hastalıkları Dergisi 2004;47:79-84.
14. Back SA, Plawner LL. Congenital malformations of the central nervous system. In: Gleason CA, Devaskar SU. eds. Avery’s Diseases of the Newborn. 9th ed. Philadelphia: Elsevier; 2012. p. 844-68.
15. Zaganjor I, Sekkarie A, Tsang BL, et al. Describing the prevalence of neural tube defects worldwide: a systematic literature review. PLos One 2016;11:e0151586.